- Home
- SPGI vs GILD Comparison
SPGI vs GILD Comparison
Compare SPGI & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SPGI | GILD |
|---|---|---|
| Founded | 1860 | 1987 |
| Country | United States | United States |
| Employees | N/A | 17600 |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.3B | 155.9B |
| IPO Year | N/A | 1992 |
Fundamental Metrics
Financial Performance| Metric | SPGI | GILD |
|---|---|---|
| Price | $526.42 | $125.84 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 20 |
| Target Price | ★ $609.31 | $127.60 |
| AVG Volume (30 Days) | 1.5M | ★ 7.0M |
| Earning Date | 02-10-2026 | 02-10-2026 |
| Dividend Yield | 0.73% | ★ 2.51% |
| EPS Growth | 21.42 | ★ 6514.05 |
| EPS | ★ 13.74 | 6.42 |
| Revenue | $15,012,000,000.00 | ★ $29,087,000,000.00 |
| Revenue This Year | $9.85 | $3.63 |
| Revenue Next Year | $7.32 | $2.97 |
| P/E Ratio | $38.26 | ★ $19.57 |
| Revenue Growth | ★ 9.04 | 2.79 |
| 52 Week Low | $427.14 | $88.57 |
| 52 Week High | $579.05 | $128.70 |
Technical Indicators
Market Signals| Indicator | SPGI | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 70.18 | 57.35 |
| Support Level | $495.00 | $118.17 |
| Resistance Level | $515.87 | $127.41 |
| Average True Range (ATR) | 7.72 | 2.89 |
| MACD | 3.09 | 0.37 |
| Stochastic Oscillator | 95.13 | 81.17 |
Price Performance
Historical ComparisonAbout SPGI S&P Global Inc.
S&P Global provides data and benchmarks to capital and commodity market participants. Its ratings business is the largest credit rating agency in the world and S&P's largest segment by profitability. S&P's largest segment by revenue is market intelligence, which provides desktop, data and advisory solutions, enterprise solutions, and credit/risk solutions mostly in the financial-services industry. S&P's other segments include commodity insights (Platts and other data), mobility (Carfax), and indexes.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).